Somatostatin receptor subtypes 2 and 5 are associated with better survival in well-differentiated endocrine carcinomas

Neuroendocrinology

Volumn 89, Issue 2, 2009, Pages 223-230

  Corleto, Vito D ^a,c,g   Falconi, Massimo ^d   Panzuto, Francesco ^a   Milione, Massimo ^a   De Luca, Ottavia ^a   Perri, Pasquale ^b   Cannizzaro, Renato ^e   Bordi, Cesare ^f   Pederzoli, Paolo ^d   Scarpa, Aldo ^d   Delle Fave, Gianfranco ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c FATEBENEFRATELLI HOSPITAL   (Italy)

^d UNIVERSITY OF VERONA   (Italy)

^e Oncologic Referral Center   (Italy)

^f UNIVERSITY OF PARMA   (Italy)

^g SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Somatostatin analogues; Somatostatin receptor; Survival rate; Well differentiated tumours

Indexed keywords

ANGIOPEPTIN; KI 67 ANTIGEN; OCTREOTIDE; RECEPTOR SUBTYPE; SOMATOSTATIN RECEPTOR 1; SOMATOSTATIN RECEPTOR 5;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; GASTRINOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RECEPTOR AFFINITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH CARCINOID; SURVIVAL RATE; TISSUE SECTION; VIPOMA;

ADULT; AGED; AGED, 80 AND OVER; ENDOCRINE GLAND NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; RECEPTORS, SOMATOSTATIN;

EID: 61749085923     PISSN: 00283835     EISSN: None     Source Type: Journal    
DOI: 10.1159/000167796     Document Type: Article

References (32)

1. Arnold R, Trautmann ME, Creutzfeldt W, et al: Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. Gut 1996;38:430-438.
2. Oberg K, Kvols L, Caplin M, et al: Consensus report on the use of somatostatin analogues for the management of neuroendocrine tumours of the gastroenteropancreatic system. Ann Oncology 2004;15:966-973.
3. Panzuto F, Nasoni S, Baccini F, et al: Unlabelled somatostatin analogue in treatment of digestive endocrine tumours. Digest Liver Dis 2004;36(suppl 1):S42-S47.
4. Patel YC: Molecular pharmacology of somatostatin receptor subtypes. J Endocrinol Invest 1997;20:348-367.
5. Corleto VD, Nasoni S, Panzuto F, et al: Somatostatin receptor subtypes: basic pharmacology and tissue distribution. Digest Liver Dis 2004;36(suppl 1):S8-S16.
6. Angeletti S, Corleto VD, Schillaci O, et al: Single dose of octreotide stabilize metastatic gastro-entero-pancreatic endocrine tumours. Ital J Gastroenterol Hepatol 1999;31:23-27.
7. Tomassetti P, Migliori M, Corinaldesi R, et al: Treatment of gastroenteropancreatic neuroendocrine tumours with octreotide LAR. Aliment Pharmacol Ther 2000;14:557-560.
8. Jais P, Terris B, Ruszniewski P, et al: Somatostatin receptor subtype gene expression in human endocrine gastroentero-pancreatic tumours. Eur J Clin Invest 1997;27:639-644.
9. Kimura N, Pilichowska M, Date F, et al: Immunohistochemical expression of somatostatin type 2A receptor in neuroendocrine tumours. Clin Cancer Res 1999;5:3483-3487.
10. Kulaksiz H, Eissele R, Rossler D, et al: Identification of somatostatin receptor subtypes 1, 2A, 3, and 5 in neuroendocrine tumours with subtype specific antibodies. Gut 2002;50:52-60.
11. Papotti M, Bongiovanni M, Volante M, et al: Expression of somatostatin receptor types 1-5 in 81 cases of gastrointestinal and pancreatic endocrine tumours: a correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis. Virchows Arch 2002;440:461-475.
12. Reubi JC, Schaer JC, Waser B, et al: Expression and localization of somatostatin receptor SSTR1, SSTR2, and SSTR3 messenger RNAs in primary human tumours using in situ hybridization. Cancer Res 1994;54:3455-3459.
13. Panzuto F, Nasoni S, Falconi M, et al: Prognostic factors and survival in endocrine tumour patients: comparison between gastrointestinal and pancreatic localization. Endocr Relat Cancer 2005;12:1083-1092.
14. Kubota A, Yamada Y, Kagimoto S, et al: Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumours. J Clin Invest 1994;93:1321-1325.
15. Butturini G, Bettini R, Missiaglia E, et al: Predictive factors of the somatostatin analogue octreotide as first line therapy for advanced pancreatic endocrine carcinoma. Endocr Relat Cancer 2006;13:1213-1221.
16. Aparicio T, Ducreux M, Baudin E, et al: Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours. Eur J Cancer 2001;37:1014-1019.
17. Delaunoit T, Rubin J, Neczyporenko F, et al: Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours. Mayo Clin Proc 2005;80:502-506.
18. Ducreux M, Ruszniewski P, Chayvialle JA, et al: The antitumoural effect of the long-acting somatostatin analogue lanreotide in neuroendocrine tumours. Am J Gastroenterol 2000;95:3276-3281.
19. Garland J, Buscombe JR, Bouvier C, et al: Sandostatin LAR (long-acting octreotide acetate) for malignant carcinoid syndrome: a 3-year experience. Aliment Pharmacol Ther 2003;17:437-444.
20. O'Toole D, Ducreux M, Bommelaer G, et al: Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance. Cancer 2000;88:770-776.
21. Ricci S, Antonuzzo A, Galli L, et al: Long-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumours. Am J Clin Oncol 2000;23:412-415.
22. Welin SV, Janson ET, Sundin A, et al: High-dose treatment with a long-acting somatostatin analogue in patients with advanced midgut carcinoid tumours. Eur J Endocrinol 2004;151:107-112.
23. Shojamanesh H, Gibril F, Louie A, et al: Prospective study of the antitumour efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma. Cancer 2002;94:331-343.
24. Corleto VD, Angeletti S, Schillaci O, et al: Long-term octreotide treatment of metastatic carcinoid tumour. Ann Oncol 2000;11:491-493.
25. Filosso PL, Ruffini E, Oliaro A, et al: Long-term survival of atypical bronchial carcinoids with liver metastases, treated with octreotide. Eur J Cardiothorac Surg 2002;21:913-917.
26. Blaker M, Schmitz M, Gocht A, et al: Differential expression of somatostatin receptor subtypes in hepatocellular carcinomas. J Hepatol 2004;41:112-118.
27. Tonnies H, Toliat MR, Ramel C, et al: Analysis of sporadic neuroendocrine tumours of the enteropancreatic system by comparative genomic hybridisation. Gut 2001;48:536-541.
28. Speel EJ, Richter J, Moch H, et al: Genetic differences in endocrine pancreatic tumour subtypes detected by comparative genomic hybridization. Am J Pathol 1999;155:1787-1794.
29. Kytola S, Hoog A, Nord B, et al: Comparative genomic hybridization identifies loss of 18q22-qter as an early and specific event in tumourigenesis of midgut carcinoids. Am J Pathol 2001;158:1803-1808.
30. Rigaud G, Missiaglia E, Moore PS, et al: High resolution allelotype of nonfunctional pancreatic endocrine tumours: identification of two molecular subgroups with clinical implications. Cancer Res 2001;61:285-292.
31. Furlan D, Cerutti R, Uccella S, et al: Different molecular profiles characterize well-differentiated endocrine tumours and poorly differentiated endocrine carcinomas of the gastroenteropancreatic tract. Clin Cancer Res 2004;10:947-957.
32. Honegger J, Prettin C, Feuerhake F, et al: Expression of Ki-67 antigen in nonfunctioning pituitary adenomas: correlation with growth velocity and invasiveness. J Neurosurg 2003;99:674-679.